ROCHE

Engimmune Therapeutics Announces the Appointment of Dr Annalisa D'Andrea to its Board of Directors

Retrieved on: 
Tuesday, May 23, 2023
Inflammation, GSK, Antigen, University, Therapy, ARCH Venture Partners, Biotechnology, Cancer, University of Florence, TCR, SRI International, Discovery, Bangladesh Technical Education Board, Publication, Novartis, Patient, Wistar Institute, Drug discovery, Growth, Immunology, University of Siena, Pharmaceutical industry

BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.

Key Points: 
  • BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.
  • Dr. D'Andrea has over 25 years of experience in the life-science industry including immunology research, drug discovery and development, and strategic leadership in biotechnology and pharmaceutical companies.
  • She is a Venture Partner at Longwood Fund and is the former President and Chief Scientific Officer of ImmuneID.
  • Dr Annalisa D'Andrea, Member of the Board of Directors at Engimmune Therapeutics commented: "I am delighted to be joining Engimmune Therapeutics at an exciting and important phase of development as the Company strives to develop new multi-specific TCR therapies for the treatment and benefit of patients with cancer and autoimmune diseases.

Engimmune Therapeutics Announces the Appointment of Dr Annalisa D'Andrea to its Board of Directors

Retrieved on: 
Tuesday, May 23, 2023
Inflammation, GSK, Antigen, University, Therapy, ARCH Venture Partners, Biotechnology, Cancer, University of Florence, TCR, SRI International, Discovery, Bangladesh Technical Education Board, Publication, Novartis, Patient, Wistar Institute, Drug discovery, Growth, Immunology, University of Siena, Pharmaceutical industry

BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.

Key Points: 
  • BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.
  • Dr. D'Andrea has over 25 years of experience in the life-science industry including immunology research, drug discovery and development, and strategic leadership in biotechnology and pharmaceutical companies.
  • She is a Venture Partner at Longwood Fund and is the former President and Chief Scientific Officer of ImmuneID.
  • Dr Annalisa D'Andrea, Member of the Board of Directors at Engimmune Therapeutics commented: "I am delighted to be joining Engimmune Therapeutics at an exciting and important phase of development as the Company strives to develop new multi-specific TCR therapies for the treatment and benefit of patients with cancer and autoimmune diseases.

Roche introduces navify® Sample Tracking for labs to track patient test samples before even reaching lab premises

Retrieved on: 
Monday, May 22, 2023
Analytics, Diagnosis, Health, Urine, ROG, RO, Phlebotomy, Collection, Laboratory, Patient, Control, LIS, PPA, Labs, Fine chemical, Television, Medical device

At Worldlab-EuroMedLab, Roche presents navify® Sample Tracking, a digital solution allowing labs to connect to innovative applications that monitor quality and detect errors in patient test samples along the entire journey to the lab.

Key Points: 
  • At Worldlab-EuroMedLab, Roche presents navify® Sample Tracking, a digital solution allowing labs to connect to innovative applications that monitor quality and detect errors in patient test samples along the entire journey to the lab.
  • navify Sample Tracking is part of the navify® Diagnostics portfolio, a set of digital solutions enabling labs to drive end-to-end operational excellence across care settings.
  • The pathway to disease diagnosis requires tracking a patient's diagnostic sample from start to finish to support clinical decisions.
  • Roche is moderating key presentations about digital technologies with lab leaders and external digital ecosystems collaborators focusing on topics such as:

Roche showcases commitment to advancing innovative diagnostic solutions at WorldLab-EuroMedLab

Retrieved on: 
Wednesday, May 17, 2023
Laboratory, Mass spectrometry, Sale, ROG, RO, Health, Neurology, PCR, Television, Fine chemical

The company will  introduce navify® digital solutions that help laboratories address their needs for digital infrastructure, operational excellence and medical insights.

Key Points: 
  • The company will  introduce navify® digital solutions that help laboratories address their needs for digital infrastructure, operational excellence and medical insights.
  • "With the ever-changing needs of the healthcare system, laboratories and clinicians are expected to optimise laboratory operations and efficiencies while improving patient care," said Ann Costello, Head of Roche Diagnostics Solutions at Roche Diagnostics.
  • "Laboratories have a unique opportunity to connect siloed data across systems and points of care for greater insights," said Moritz Hartmann, Head of Roche Information Solutions at Roche Diagnostics.
  • Roche will also introduce its navify digital solutions to the laboratory community.

Roche showcases commitment to advancing innovative diagnostic solutions at WorldLab-EuroMedLab

Retrieved on: 
Wednesday, May 17, 2023
Laboratory, Mass spectrometry, Sale, ROG, RO, Health, Neurology, PCR, Television, Fine chemical

The company will  introduce navify® digital solutions that help laboratories address their needs for digital infrastructure, operational excellence and medical insights.

Key Points: 
  • The company will  introduce navify® digital solutions that help laboratories address their needs for digital infrastructure, operational excellence and medical insights.
  • "With the ever-changing needs of the healthcare system, laboratories and clinicians are expected to optimise laboratory operations and efficiencies while improving patient care," said Ann Costello, Head of Roche Diagnostics Solutions at Roche Diagnostics.
  • "Laboratories have a unique opportunity to connect siloed data across systems and points of care for greater insights," said Moritz Hartmann, Head of Roche Information Solutions at Roche Diagnostics.
  • Roche will also introduce its navify digital solutions to the laboratory community.

Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Thursday, May 11, 2023
Spark Therapeutics, Chronic granulomatous disease, Intellectual property, Patent, Pfizer, Bleeding, Gene, CHOP, Eye, Food and Drug Administration, RNA, G&A, Retina, Sale, Novartis, Investment, Patient, Cancer, Annual general meeting, Cell, CGD, American Society of Gene and Cell Therapy, Liver, Prime editing, R, Research, Therapy, Society, Food, DSM-IV codes, D, Management, Cryptocurrency, Pharmaceutical industry, Vaccine, Video game, Spark, IND

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the first quarter ended March 31, 2023.

Key Points: 
  • 17/751,599 --
    -- Cash, cash equivalents, investments and restricted cash balance of $263.0 million as of March 31, 2023 --
    CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the first quarter ended March 31, 2023.
  • In April 2023, Prime Medicine received a notice of allowance from the U.S. PTO for its third patent application, No.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Initiate investigational new drug (IND)-enabling studies for PM359 in CGD in 2023.
  • Maximize Prime Editing’s broad therapeutic potential and create value through strategic business development that extends the reach and impact of Prime Editing to areas beyond Prime Medicine’s current areas of focus.

HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, May 11, 2023
KRAS, Gilead Sciences, Biotechnology, Arenavirus, Research, Trial of the century, Gilead, ASCO, Development, American Society of Clinical Oncology, Administration, Annual general meeting, Pembrolizumab, Society, Compensated emancipation, Pharmaceutical industry, Satellite navigation device, Cryptocurrency

NEW YORK and VIENNA, May 11, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2023.

Key Points: 
  • NEW YORK and VIENNA, May 11, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and business highlights for the first quarter of 2023.
  • The success-based milestone payment reflects the start of the HB-700 manufacturing process to support a Phase 1 clinical trial.
  • In March, HOOKIPA announced the appointment of Terry Coelho to its Board of Directors , Audit Committee and Compensation Committee.
  • Terry brings more than 35 years of experience in business strategy, broad financial transactions and business development of large pharmaceutical and smaller biotechnology companies.

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 10, 2023
Bevacizumab, Society, AACR, Annual Meetings of the International Monetary Fund and the World Bank Group, Therapy, Hepatocellular carcinoma, RECIST, SITC, Immunotherapy, Research, TREX1, ASCO, American Society of Clinical Oncology, Standard of care, Patient, Annual general meeting, HCC, Pembrolizumab, ORR, Pharmaceutical industry, Arms industry, Cryptocurrency, Tempest

BRISBANE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • BRISBANE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended March 31, 2023 and provided a corporate update.
  • “The first few months of 2023 set the pace for what we believe will be a transformative year for Tempest,” said Stephen Brady, chief executive officer of Tempest.
  • Tempest ended the first quarter with $22.9 million in cash and cash equivalents, compared to $31.2 million on December 31, 2022.
  • Based on the current cash position and operating plan, Tempest expects to have sufficient resources to fund operations through the second quarter of 2024.

XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy

Retrieved on: 
Tuesday, May 9, 2023
Face, G&A, Acquisition, Research, Sales, Video game, Cryptocurrency, Rezolution Pictures

EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2023 financial results and highlighted recent operational achievements as the Company accelerates XOMA’s differentiated biotech royalty and milestone acquisition strategy.

Key Points: 
  • EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its first quarter 2023 financial results and highlighted recent operational achievements as the Company accelerates XOMA’s differentiated biotech royalty and milestone acquisition strategy.
  • “In the first quarter, the team acted rapidly and decisively to add a second cashflow-generating, long-duration asset to XOMA’s milestone and royalty portfolio.
  • In February, we received a payment related to the commercial sales of Vabysmo® (faricimab) during the second half of 2022.
  • General and administrative (“G&A”) expenses were $6.2 million for the first quarter of 2023, compared to $5.1 million for the first quarter of 2022.

Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor

Retrieved on: 
Tuesday, May 9, 2023
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Partnership, Brain, CSO, HER2, Traffic barrier, Breast, Permeability, Patient, Entrepreneurship, Disease, Medical imaging

Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041.

Key Points: 
  • Zion Pharma Limited, a Chinese biotechnology company focused on the development of brain-penetrable compounds, today announced that Roche has acquired the global rights to Zion’s lead program, ZN-A-1041.
  • ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2).
  • ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer.
  • Up to 50% of patients with HER2-positive metastatic breast cancer will develop brain metastasis during the course of the disease.